Nestlé ups stake in Aimmune

6 February 2020

US food allergies specialist Aimmune Therapeutics (Nasdaq: AIMT) yesterday announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in the firm to date to $473 million.

The news comes shortly after Aimmune was granted the first ever Food and Drug Administration for peanut allergy treatment, the company’s Palforzia (Peanut [Arachis hypogaea] allergen powder-dnfp), and caused the firm’s shares to rise 3.1% to $30.28 by close of trading yesterday.

After the completion of the transaction, Nestlé Health Science’s total investments in Aimmune will correspond to ownership of 19.9% of Aimmune’s outstanding common stock and voting power, and 25.6% overall stake in the company’s fully-diluted capitalization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK